Abstract
背景与目的已有研究表明分子标志物在指导肺癌个体化治疗中起着重要作用。本研究旨在探讨非小细胞肺癌（non-small cell lung cancer, NSCLC）抗微管类药物靶点TUBB3（tubulin, beta 3 class Ⅲ)/STMN1（stathmin 1）基因表达水平与EGFR（epidermal growth factor receptor）、KRAS（Kirsten rat sarcoma viral oncogene homolog）、BRAF（v-raf murine sarcoma viral oncogene homolog B）、PI3K（phosphatidylinositol-4, 5-bisphosphate 3-kinase）基因突变的相关性，为NSCLC预后及药物疗效判断提供参考依据。方法回顾性分析我院经病理确诊的46例NSCLC患者手术切除的肿瘤标本，通过分支DNA-液相芯片法检测TUBB3、STMN1基因mRNA表达水平，通过xTAG液相芯片法检测EGFR、KRAS、BRAF、PI3K基因突变，对检测结果应用SPSS 19.0软件采用Spearman相关进行分析基因表达与基因突变的关系。结果抗微管靶点TUBB3和STMN1存在很强的共表达性，TUBB3基因高表达时，STMN1趋向于高表达（P=0.006）。EGFR E21突变与TUBB3存在负相关关系：EGFR E21无突变时TUBB3趋向于高表达（P=0.004, 6）。KRAS E2突变与STMN1存在正相关关系：KRAS E2突变时STMN1趋向于高表达（P=0.038, 6）。结论抗微管耐药相关因子TUBB3和STMN1与EGFR通路的关键因子突变相关，提示了EGFR突变和KRAS突变是调控TUBB3/STMN1表达的重要因素，为研究化疗药物耐药性提供了重要的参考因素。
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
